Approximately 70% of breast cancers express ERα; since estrogen-mediated ERα signaling plays a central role in the progression of these cancers, ERα is a prime therapeutic target for ER-positive breast cancer patients. The gene discussed is ERAS; the disease is breast carcinoma.